Mersana Therapeutics reports third quarter 2025 financial results
Mersana Therapeutics Inc. reported a net loss of $7.5 million for Q3 2025, an improvement from a $11.5 million loss in Q3 2024. General and administrative expenses decreased to $6.3 million from $9.9 million. Cash and equivalents totaled $56.4 million as of September 30, 2025. The company will be acquired by Day One Biopharmaceuticals Inc., with the deal closing expected by January 2026.
Mersana Therapeutics Inc. reported a net loss of $7.5 million, or $1.51 per share, for the third quarter of 2025, compared to a net loss of $11.5 million, or $2.34 per share, in the same period of 2024. General and administrative expenses for the third quarter of 2025 were $6.3 million, down from $9.9 million in the third quarter of 2024. As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $56.4 million, compared to $134.6 million at December 31, 2024. The company announced it has entered into an agreement to be acquired by Day One Biopharmaceuticals Inc., with closing expected by the end of January 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mersana Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-111929), on November 14, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
